FibroBiologics prices combined unit offering at $4.40 and 1-for-20 reverse split to regain Nasdaq compliance

FibroBiologics has priced a combined unit offering at $4.40. This move is designed to help the company regain compliance with Nasdaq listing requirements, following a 1-for-20 reverse stock split.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin